Lilly's amylin-Zepbound combo shows up to 23.3% weight loss in obesity-diabetes patients at EASD 2026

Lilly presented new data on its amylin‑Zepbound combination at the European Association for the Study of Diabetes meeting in Milan. The trial focused on patients who have both obesity and type 2 diabetes.

The results indicated a maximum weight reduction of about 23.3 percent, which the company described as the best‑ever outcome for this patient group. The findings were highlighted as a potential advancement over existing obesity therapies.

While the report did not include detailed safety or long‑term efficacy information, the magnitude of weight loss suggests the combo could become a notable option for clinicians treating metabolic disease.

The announcement underscores Lilly's continued investment in dual‑targeted approaches that pair amylin analogues with GLP‑1 receptor agonists, aiming to address the growing demand for effective obesity and diabetes treatments.